about
Update on inflammatory breast cancerInflammatory breast cancer: New factors contribute to disease etiology: A reviewMarkers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherinNF-kappa B genes have a major role in inflammatory breast cancerMutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients.Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer.Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancerGPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.Skin involvement and breast cancer: are T4b lesions of all sizes created equal?Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancerCirculating tumor cells in newly diagnosed inflammatory breast cancer.Neoadjuvant chemotherapy for cervical cancer.Prognostic significance of HER-2 status in women with inflammatory breast cancerInflammatory breast cancer: is it really a separate entity?A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.A comparison of cholesterol uptake and storage in inflammatory and noninflammatory breast cancer cells.Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up.The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cellsCirculating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer.Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer.EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer.p53 protein accumulation and presence of visceral metastasis are independent prognostic factors for survival in patients with metastatic inflammatory breast carcinoma.Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment.Expression of WISP3 and RhoC genes at mRNA and protein levels in inflammatory and noninflammatory breast cancer in Tunisian patients.Metastatic esophageal carcinoma masquerading as inflammatory breast carcinoma.High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy.Coping with inflammatory breast cancer: women's experiences.TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase.Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies.
P2860
Q24797853-FC6CA321-C896-48EE-882B-072FE97000D2Q27027856-E9979F7D-A123-45AE-8BBB-F29D77A62FDEQ33317058-6F3DCE1A-0690-45A4-99F8-43CEE36F541DQ33318125-C7BA9E09-B1D0-41FD-9DA8-51367F246C70Q33618285-1E3AEA36-95C1-430A-BF72-805981728B99Q33751139-D9560C39-65E1-4A81-8E94-5AE1A7AD1D44Q33829270-8F2B20CE-C74D-49B2-8C6D-2834312B921EQ33942512-79BB1108-67DA-46D7-B2B2-A5949B47C358Q33996321-C70A3ECA-DE58-4B05-A376-716EBCA59BF0Q34084392-B2F518AB-1A30-4103-96BC-34D25B6B6B6DQ35007782-00D9C3A5-F557-4BAF-9407-09F42F188D65Q35052773-4B6DFBA4-EF9C-4C1D-95CC-854E838099A5Q35143934-469A773D-E75C-49D2-90AD-2F2BF9C6C7F5Q35624765-1246409E-C37A-48D2-8443-4E9E68B3E712Q35939285-3908851A-6118-46BF-8C5F-D073BD4BEDABQ36514752-B14BA0A5-C6C2-4EE5-8136-5BF211DD7811Q36546465-01D139F6-400A-4E2E-BD12-88B7FC52338BQ36611240-46CEDEB9-F9F5-4C96-A257-DEA2BA8F098CQ36725203-1A4DBE7D-B6B4-44BE-A081-EA8B8EBD7370Q36848095-4699A058-24A5-4F3E-9064-B0E63B68030CQ37015722-F14A0118-B16A-40E0-9DC5-DB3BC36BAD2EQ42243028-AC2666FC-DAB4-4673-BCA3-099CC959A671Q44674958-819E444D-9724-463B-82A5-1268C4ABDBBFQ44788997-BAF931E9-4B0D-49D2-927B-1738E81BD37EQ46511043-70813558-DF26-47AD-AAB0-D5D96C4B5C8BQ50703194-47A2CE83-CA81-4122-8358-71C87FC3D931Q51813446-D912296C-94D2-4925-B77E-F919563544F5Q51901480-957C9D33-CEE3-4F57-A6F3-5DEB75A5CBC3Q53090999-534125E5-9188-4ABF-BF7E-458F8B5537FFQ54967454-E28FB1E3-F343-4971-BFE7-A36BA9244F7A
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Update on the management of inflammatory breast cancer.
@ast
Update on the management of inflammatory breast cancer.
@en
type
label
Update on the management of inflammatory breast cancer.
@ast
Update on the management of inflammatory breast cancer.
@en
prefLabel
Update on the management of inflammatory breast cancer.
@ast
Update on the management of inflammatory breast cancer.
@en
P2093
P1433
P1476
Update on the management of inflammatory breast cancer.
@en
P2093
Aman U Buzdar
Gabriel N Hortobágyi
Massimo Cristofanilli
P304
P356
10.1634/THEONCOLOGIST.8-2-141
P577
2003-01-01T00:00:00Z